검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Therapeutic Hydrocortisone (Therapeutic Hydrocortisone) Neurocrine UK Limited·Acute Myeloid Leukemia ORR 6% |
|---|---|
Overview Program | Therapeutic Hydrocortisone |
Overview Company | Neurocrine UK Limited |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Adult Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | , structure-activity relationship (SAR), molecular interactions (via in silico docking), and influence on cortisol metabolism in LX-2 cells |
MoA Biomarker | biomarker of GH deficiency in PCC patients |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Diagnostic Value of Key Clinical Characteristics and Baseline Cortisol in Assessing Adrenal Function in Patients Receiving Glucocorticoid Therapy.. Prolonged glucocorticoid therapy may result in multi-organ complications and adrenal insufficiency (AI). To mitigate these risks, clinicians typically taper and discontinue treatment once the underlying disease is controlled. Prior to withdrawal, adren… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 6% |
Clinical PFS | 4.7 |
Clinical OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Therapeutic Hydrocortisone (Therapeutic Hydrocortisone) Neurocrine UK Limited·Acute Myeloid Leukemia ORR 6% |
|---|---|
Overview Program | Therapeutic Hydrocortisone |
Overview Company | Neurocrine UK Limited |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Adult Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | , structure-activity relationship (SAR), molecular interactions (via in silico docking), and influence on cortisol metabolism in LX-2 cells |
MoA Biomarker | biomarker of GH deficiency in PCC patients |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Diagnostic Value of Key Clinical Characteristics and Baseline Cortisol in Assessing Adrenal Function in Patients Receiving Glucocorticoid Therapy.. Prolonged glucocorticoid therapy may result in multi-organ complications and adrenal insufficiency (AI). To mitigate these risks, clinicians typically taper and discontinue treatment once the underlying disease is controlled. Prior to withdrawal, adren… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 6% |
Clinical PFS | 4.7 |
Clinical OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교